Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05390606
Other study ID # FRT0322
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date June 15, 2022
Est. completion date March 20, 2023

Study information

Verified date July 2023
Source Vaginal Biome Science
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study intends to address whether improving the vaginal microbiome can help couples increase chances of conceiving.


Description:

Disrupted vaginal microbiomes are associated with a number of poor reproductive outcomes, including infertility, miscarriage, premature rupture of membranes, preterm labor and delivery, delivery of a low birthweight baby, and maternal infections (chorioamnionitis, endometritis). A healthy vaginal microbiome is typically thought to be one that is dominated by one of several Lactobacillus species, such as L. crispatus, L. gasseri, or L. jensenii. Several studies have shown that non-lactobacilli-dominant biomes are associated with poor in vitro fertilization or intrauterine insemination outcomes. Fewer studies have examined fertility in the home setting, and none to date has asked whether improving the vaginal microbiome (VMB) could increase fertility. This study addresses both. By assessing the VMB before and after using a vaginal care system which supports a healthy VMB, we will be able to examine whether there are associations between VMB composition and infertility, and whether shifting the VMB toward a lactobacillus-dominant state is able to improve chances of conception. In this study, women will either follow routine care (control) or routine care plus the vaginal care system and fertility lubricant (intervention) for 3 months or until becoming pregnant, whichever comes first. In addition to tracking conception rates during those 3 months, we will follow women for an additional year following completion of the 3-month timeframe. If any woman is pregnant at the one-year mark, her pregnancy will be followed until delivery (or early termination) to track delivery outcomes and adverse events.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date March 20, 2023
Est. primary completion date March 20, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: Women part of a cisgender couple aged 18 to 40 who are attempting to become pregnant and are attending a fertility clinic. Exclusion Criteria: 1. Pregnant 2. Lactating 3. Severe male factor, hormonal imbalance (oligoovulatory/anovulatory cycles, cycles longer than 35 days), genetic abnormalities (chromosomal abnormality, common genetic mutation between partners), or severe uterine or tubal factor 4. Any diagnosis that would require the participant to undergo in vitro fertilization to become pregnant 5. Known allergies to any component of BioNourish®, Balance, BiopHresh®, or BioGenesis™ 6. Known active vaginal infection at enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Flourish HEC and BioGenesis
Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.

Locations

Country Name City State
United States Dr. Aimee Eyvazzadeh San Ramon California

Sponsors (2)

Lead Sponsor Collaborator
Vaginal Biome Science Dr. Aimee Eyvazzadeh, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Conception at home Percentage of women becoming pregnant at home within the 3 month study. 3 months
Primary Change in vaginal microbiome Vaginal microbiome composition tested by next-generation sequencing Baseline to end of active study period, which is either at 3 months or upon confirmation of pregnancy, whichever occurs first.
Primary Change in vaginal pH Vaginal pH tested by vaginal fluid applied to pH test strip Baseline to end of active study period, which is either at 3 months or upon confirmation of pregnancy, whichever occurs first.
Secondary Conception within one year Percentage of women becoming pregnant by any method within the 3 month study or within one year after ending the study. 15 months
Secondary Rate of live birth Percentage of women giving live birth within one year after ending the study; or if pregnant at one year, following to the end of her pregnancy. 24 months or fewer
Secondary Gestational age at delivery Average gestational age of babies born within one year after ending the study; or if mothers are pregnant at one year, following to the end of her pregnancy. 24 months or fewer
Secondary Birthweight at delivery Average weight of babies born within one year after ending the study; or if mothers are pregnant at one year, following to the end of her pregnancy. 24 months or fewer
Secondary Rates of pregnancy complications Percentage of women experiencing complications (including preeclampsia, miscarriage/fetal loss/stillbirth, preterm/premature rupture of membranes, chorioamnionitis or endometritis, gestational diabetes, and any other adverse outcome) within one year after ending the study; or if mothers are pregnant at one year, following to the end of her pregnancy. 24 months or fewer
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A